Literature DB >> 6946467

Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins.

M B Penno, B H Dvorchik, E S Vesell.   

Abstract

Adult, male, unmedicated twins received antipyrine orally under carefully controlled environmental conditions. Relative contributions of genetic and environmental factors to 2-fold interindividual variations in rate constants for formation of the three main antipyrine metabolites were compared. Heritabilities for rate constants for formation of 4-hydroxyantipyrine, N-demethylantipyrine, and 3-hydroxymethylantipyrine were 0.88, 0.85, and 0.70, respectively. These results suggest that each molecular form of cytochrome P-450 that converts antipyrine to a different metabolite exhibits genetically controlled interindividual variations in activity. Unrelated adult male subjects whose environments were also carefully controlled exhibited highly reproducible rate constants for formation of antipyrine metabolites. Because the rate constant for metabolite formation sensitively detects certain variations in the gene product, it should be used in future pharmacogenetic studies on rates of production of multiple metabolites from a single parent drug.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6946467      PMCID: PMC320370          DOI: 10.1073/pnas.78.8.5193

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  93 in total

1.  The origin of the polydispersity in sedimentation patterns of rapidly labelled nuclear ribonucleic acid.

Authors:  M E Bramwell; H Harris
Journal:  Biochem J       Date:  1967-06       Impact factor: 3.857

2.  Genetic control of drug levels in man: antipyrine.

Authors:  E S Vesell; J G Page
Journal:  Science       Date:  1968-07-05       Impact factor: 47.728

3.  Metabolism of drugs. LIX. A new metabolite of antipyrine.

Authors:  H Yoshimura; H Shimeno; H Tsukamoto
Journal:  Biochem Pharmacol       Date:  1968-08       Impact factor: 5.858

4.  Patterns of RNA metabolism in a differentiated cell: a rapidly labeled, unstable 60S RNA with messenger properties in duck erythroblasts.

Authors:  K Scherrer; L Marcaud; F Zajdela; I M London; F Gros
Journal:  Proc Natl Acad Sci U S A       Date:  1966-11       Impact factor: 11.205

Review 5.  Retroviral transforming genes in normal cells?

Authors:  P H Duesberg
Journal:  Nature       Date:  1983 Jul 21-27       Impact factor: 49.962

6.  Rapidly labeled HeLa cell nuclear RNA. I. Identification by zone sedimentation of a heterogeneous fraction separate from ribosomal precursor RNA.

Authors:  J R Warner; R Soeiro; H C Birnboim; M Girard; J E Darnell
Journal:  J Mol Biol       Date:  1966-08       Impact factor: 5.469

7.  Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

8.  Human beta and delta globin messenger RNAs turn over at different rates.

Authors:  J Ross; A Pizarro
Journal:  J Mol Biol       Date:  1983-07-05       Impact factor: 5.469

9.  Nucleotide sequence analysis of the delta beta-globin gene region in humans.

Authors:  M Poncz; E Schwartz; M Ballantine; S Surrey
Journal:  J Biol Chem       Date:  1983-10-10       Impact factor: 5.157

10.  ATA box transcription mutation in beta-thalassemia.

Authors:  S H Orkin; J P Sexton; T C Cheng; S C Goff; P J Giardina; J I Lee; H H Kazazian
Journal:  Nucleic Acids Res       Date:  1983-07-25       Impact factor: 16.971

View more
  17 in total

Review 1.  Alzheimer disease.

Authors:  David S Knopman; Helene Amieva; Ronald C Petersen; Gäel Chételat; David M Holtzman; Bradley T Hyman; Ralph A Nixon; David T Jones
Journal:  Nat Rev Dis Primers       Date:  2021-05-13       Impact factor: 52.329

Review 2.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

3.  Variability in biological monitoring of solvent exposure. I. Development of a population physiological model.

Authors:  P O Droz; M M Wu; W G Cumberland; M Berode
Journal:  Br J Ind Med       Date:  1989-07

4.  High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.

Authors:  M Apellániz-Ruiz; L Inglada-Pérez; M E G Naranjo; L Sánchez; V Mancikova; M Currás-Freixes; A A de Cubas; I Comino-Méndez; S Triki; A Rebai; M Rasool; G Moya; M Grazina; G Opocher; A Cascón; P Taboada-Echalar; M Ingelman-Sundberg; A Carracedo; M Robledo; A Llerena; C Rodríguez-Antona
Journal:  Pharmacogenomics J       Date:  2014-11-04       Impact factor: 3.550

5.  Simplified approaches to the determination of antipyrine pharmacokinetic parameters.

Authors:  J M Scavone; D J Greenblatt; G T Blyden; J S Harmatz; P J Graziano
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

6.  Isolation and sequence of a human cytochrome P-450 cDNA clone.

Authors:  I R Phillips; E A Shephard; A Ashworth; B R Rabin
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

7.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

Review 8.  Assessment of methods to identify sources of interindividual pharmacokinetic variations.

Authors:  E S Vesell; M B Penno
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

9.  Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Method.

Authors:  Jian Shi; Xinwen Wang; Huaijun Zhu; Hui Jiang; Danxin Wang; Alexey Nesvizhskii; Hao-Jie Zhu
Journal:  J Proteome Res       Date:  2018-09-04       Impact factor: 4.466

10.  The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

Authors:  F Broly; N Vandamme; C Libersa; M Lhermitte
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.